RUA Life Sciences Sees Strong Revenue Growth
Company Announcements

RUA Life Sciences Sees Strong Revenue Growth

RUA Life Sciences (GB:RUA) has released an update.

RUA Life Sciences reports a robust first-half revenue growth, doubling from last year, driven by increased biomaterials royalties and contract manufacturing revenues. The group’s strategic acquisition of Abiss Group has bolstered its financial standing, with a pre-tax profit of £0.4 million, a significant recovery from a loss last year. The company is also adjusting its accounting year to align better with business planning.

For further insights into GB:RUA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskRUA Life Sciences Acquires Medical Device Firm Abiss
TipRanks UK Auto-Generated NewsdeskRUA Life Sciences AGM Concludes with Full Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App